Bayer announced it plans to increase sales for its main Healthcare division by 6 percent on average through 2017 to more than $26.7 billion by hanging its hat on new drugs, such as the blood thinner Xarelto. The company says rising sales of these newer drugs have helped offset declines of its birth control pill and multiple sclerosis treatment in the face of competition. Bayer teamed up with Johnson & Johnson subsidiary Janssen Pharmaceuticals to produce Xarelto, which became the second drug in a new class of blood thinners called Xa inhibitors. The anticoagulant is used to prevent or treat blood ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.